Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors
Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olaparib and adavosertib, if they are given in sequence rather than concurrently.
Oct 27, 2022
0
4